Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Diseases currently targeted include pneumonia, H1N1, bird flu, enterovirus, encephalitis, rabies, meningitis and others.
The company announced today the submission of applications to commence human clinical trials for its 23-valent and 24-valent pneumococcal polysaccharides vaccines (PPV) to the Chinese State Food Drug Administration. The preclinical studies were completed and showed good safety and efficacy profile in animal models.
The current available 23-valent PPV has shown good protection effects after launching into the Chinese market. But due to the different epidemic characteristics of pneumococcal dieseases in China, Sinovac also developed the 24-valent PPV to cover one more type of pneumococcus, which is one of the top three most prevalent pneumococcus bacteria in China. It therefore has the potential to provide more extensive vaccine protection to the Chinese population.
Sinovac independently developed the vaccines and will retain full commercialization rights to the vaccine upon approval. The supplied quantity of PPV has doubled in China over the past three years. This demonstrates the increasing demand in China for these type of vaccines. The gap between supply and demand for PPV is still quite extensive, which bodes well for Sinovac’s future profitability.
For further information on Sinovac Biotech, please visit the company’s website at www.sinovac.com